Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy.

Curr Opin Allergy Clin Immunol

Department of Pediatrics, and the Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, School of Medicine, La Jolla, California 92093-0833, USA.

Published: December 2002

Purpose Of Review: To summarize the data of both preclinical studies and initial clinical trials of a novel allergoid for allergen specific immunotherapy. This allergoid consists of allergen covalently coupled to immunostimulatory oligodeoxynucleotide DNA sequences.

Recent Findings: Recently, immunostimulatory oligodeoxynucleotide sequences, also called unmethylated cytosin-guanine dinucleotide motifs, have been discovered that act as strong T helper 1 response inducing adjuvants in mice. Although mixing allergens with immunostimulatory DNA sequences induces T helper 1 responses in T helper 2 biased mice, the allergens in such mixes could still cause anaphylactic reactions when used in humans which is one of the reasons why immunotherapy has gradually been falling out of favor. Therefore, we made allergen-immunostimulatory oligodeoxynucleotide conjugates and investigated their immunogenicity and allergenicity in animal models of allergy. These conjugates were highly immunogenic for inducing T helper 1-like antiallergen responses and reversed T helper 2 responses and symptoms of asthma in mouse models. They were also less allergenic, as shown by the reaction with human immunoglobulin E antibodies and by histamine release from basophils of allergic patients. Preliminary phase I and II trials in ragweed allergic patients showed that allergen-immunostimulatory oligodeoxynucleotide conjugates are well tolerated, less allergenic and induce immunoglobulin G antiallergen antibodies more rapidly than allergen extracts without significantly increasing the immunoglobulin E titer.

Summary: Allergen-immunostimulatory DNA conjugates induce T helper 1 and down regulate preexisting T helper 2 anti-allergen responses in mice. Initial phase I and II trials in ragweed allergic patients showed that ragweed allergen-DNA conjugates are well tolerated and induce a rapid immunoglobulin G but not E response. The data show that allergen-DNA conjugates are a novel type of allergoid that have great potential for a safe and potent form of allergen specific immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00130832-200212000-00012DOI Listing

Publication Analysis

Top Keywords

allergen-immunostimulatory oligodeoxynucleotide
12
allergic patients
12
novel allergoid
8
allergen specific
8
specific immunotherapy
8
immunostimulatory oligodeoxynucleotide
8
helper responses
8
oligodeoxynucleotide conjugates
8
phase trials
8
trials ragweed
8

Similar Publications

Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy.

Curr Opin Allergy Clin Immunol

December 2002

Department of Pediatrics, and the Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, School of Medicine, La Jolla, California 92093-0833, USA.

Purpose Of Review: To summarize the data of both preclinical studies and initial clinical trials of a novel allergoid for allergen specific immunotherapy. This allergoid consists of allergen covalently coupled to immunostimulatory oligodeoxynucleotide DNA sequences.

Recent Findings: Recently, immunostimulatory oligodeoxynucleotide sequences, also called unmethylated cytosin-guanine dinucleotide motifs, have been discovered that act as strong T helper 1 response inducing adjuvants in mice.

View Article and Find Full Text PDF

Immunotherapy (IT) by injection more readily induces clinical tolerance to stinging insects than to respiratory allergens. However, while systemic immunization induces adaptive responses systemically, the induction of mucosal immunity generally requires local Ag exposure. Taken together, these observations suggest that the poor success rate of systemic IT for asthma could be a consequence of inadequate immune modulation in the airways.

View Article and Find Full Text PDF

Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts.

Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!